127 related articles for article (PubMed ID: 10872040)
1. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland.
Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S
Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
3. TV-image analysis based quantification of the proliferative activity and the apoptotic rate in thyroid tumors and thyroiditis.
Biesterfeld S; Rickert D; Eichler S; Fürste K; Mrusek S; Alfer J
Anticancer Res; 2003; 23(5b):4269-75. PubMed ID: 14666637
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 immunohistometry on Tru-cut biopsies in inflammatory and cirrhotic liver disease.
Biesterfeld S; Hoffmann E
Anal Quant Cytol Histol; 1998 Aug; 20(4):268-74. PubMed ID: 9739409
[TBL] [Abstract][Full Text] [Related]
5. [Role of the MIB-1 proliferative markers in the diagnosis and prognosis of tumors of the thyroid gland].
Ludvíková M; Ryska A; Hovorková E; Pikner R
Cesk Patol; 2002 Jan; 38(1):4-10. PubMed ID: 11933461
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
7. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
[TBL] [Abstract][Full Text] [Related]
8. [HBME-1 and cyclin D1 as diagnostic markers for follicular thyroid carcinoma].
Moyano L; Franco C; Carreño L; Robinson P; Sánchez G
Rev Med Chil; 2004 Mar; 132(3):279-84. PubMed ID: 15376563
[TBL] [Abstract][Full Text] [Related]
9. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 and AgNOR proliferative markers as diagnostic adjuncts to fine needle aspiration cytology of thyroid follicular lesions.
Mehrotra A; Goel MM; Singh K
Anal Quant Cytol Histol; 2002 Aug; 24(4):205-11. PubMed ID: 12199321
[TBL] [Abstract][Full Text] [Related]
11. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.
Lai X; Umbricht CB; Fisher K; Bishop J; Shi Q; Chen S
J Proteomics; 2017 Aug; 166():59-67. PubMed ID: 28709933
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions.
Lewy-Trenda I; Bieńkiewicz M
Pol J Pathol; 1999; 50(3):129-38. PubMed ID: 10624114
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
Haghpanah V; Shooshtarizadeh P; Heshmat R; Larijani B; Tavangar SM
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):422-5. PubMed ID: 17122639
[TBL] [Abstract][Full Text] [Related]
15. The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors.
Sigstad E; Paus E; Bjøro T; Berner A; Grøholt KK; Jørgensen LH; Sobrinho-Simões M; Holm R; Warren DJ
Mod Pathol; 2012 Apr; 25(4):537-47. PubMed ID: 22157935
[TBL] [Abstract][Full Text] [Related]
16. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy.
Mehrotra P; Gonzalez MA; Johnson SJ; Coleman N; Wilson JA; Davies BR; Lennard TW
Laryngoscope; 2006 Aug; 116(8):1434-8. PubMed ID: 16885749
[TBL] [Abstract][Full Text] [Related]
17. The influence of the vascularisation of the follicular thyroid nodules on the proliferative activity of the follicular cells.
ŁEbkowska UM; Dziecioł J; Lemancewicz D; Bogusłowicz W; Lewszuk A
Folia Morphol (Warsz); 2004 Feb; 63(1):79-81. PubMed ID: 15039906
[TBL] [Abstract][Full Text] [Related]
18. Role of Ki-67 as a proliferative marker in lesions of thyroid.
Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
[TBL] [Abstract][Full Text] [Related]
19. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET
J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
